Infinimmune Appoints Srikanth Pendyala as Chief Medical Officer

Infinimmune, a biotechnology company pioneering antibody discovery and design, has appointed Srikanth Pendyala, M.D., as Chief Medical Officer.

Pendyala will lead clinical and regulatory strategy across Infinimmune’s pipeline, including first-in-human trials of IFX-101 and IFX-201.

“Srikanth has spent his career building clinical programs against the targets that define modern immunology—IL-13, IL-22, IL-4R⍺, IL-17, TGF-β and IL-33,” said Wyatt McDonnell, CEO & Co-Founder, Infinimmune. “He is joining at the moment our first programs move into patients, beginning with trials of IFX-101 and IFX-201 in 2027, and his judgment will shape our clinical execution.”

Experience

Pendyala brings more than 25 years of experience advancing immunology and inflammation therapies. Prior to joining Infinimmune, he was Chief Medical Officer at multiple early stage biotechs including Endeavor Biomedicines, where he led clinical strategy and regulatory interactions for immunofibrosis programs.

Earlier in his career, Pendyala held senior clinical development roles at BridgeBio, Theravance Biopharma, Merck, and Roche/Genentech, where he contributed to the development of multiple immunology and respiratory therapies.

Pendyala completed clinical fellowships in Allergy & Immunology at The Johns Hopkins University and The Ohio State University and completed postgraduate training in Clinical Pharmacology, Drug Development & Regulation at Tufts University School of Medicine. He has held faculty appointments at the University of Chicago and the University of Illinois at Chicago and has published more than 30 peer‑reviewed articles in immunology and inflammatory biology.

“After 25 years of developing immunology therapeutics, it’s clear that the drugs that work best in patients tend to resemble what the human immune system already makes,” said Pendyala. “Infinimmune starts from those antibodies rather than engineering toward them, and I’m excited to join and begin translating that into clinical programs.”